Machine-learning analysis identifies a plasma protein signature associated with ALS years before symptoms
In a plasma-proteomics study, machine learning selected a 17-protein panel from 33 proteins that differed between 183 people with ALS and 309 controls. The panel distinguished ALS from healthy participants and other neurological diseases in a held-out test set (AUC 96.2%, balanced accuracy 89.3%) and was assessed in independent cohorts, including UK Biobank samples. Applying the model to presymptomatic samples from people who later developed ALS showed risk-score shifts up to about 10 years before symptom onset.
Technology: Machine-learning classification model trained on Olink plasma proteomic features
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: The panel distinguished ALS from healthy participants and other neurological diseases in a held-out test set (AUC 96.2%, balanced accuracy 89.3%) and was assessed in independent cohorts, including UK Biobank samples.
- Still unknown: This is a candidate biomarker result, not a clinically available diagnostic or screening test. The discovery and neurological-disease test cohorts are modest; the presymptomatic analysis is retrospective, and broader ancestry representation and prospective longitudinal validation remain needed. The paper reports multiple cohort-specific metrics; the summary uses the detailed held-out test-set AUC and balanced accuracy rather than the abstract’s 98.3% model figure.
- AI role: The model selected a multiplex protein signature and classified ALS versus healthy and neurological-disease controls; the researchers then applied its risk score to presymptomatic samples to estimate disease-associated changes before onset.
Evidence sources: https://www.nature.com/articles/s41591-025-03890-6
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 65 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.